Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of dersimelagon in diffuse cutaneous systemic sclerosis
2020-000134-17Phase 2Unknown
- Sponsor
- Mitsubishi Tanabe Pharma Development America
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing dersimelagon with placebo (2 arms). Primary endpoint: American College of Rheumatology Composite Response Index in Diffuse Systemic Sclerosis composite score. Status: unknown.
02
Drugs
dersimelagon
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2020-000134-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000134-17.